S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

ImmunoPrecise Antibodies Stock Forecast, Price & News

-0.15 (-3.49%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
22,484 shs
Average Volume
14,833 shs
Market Capitalization
$102.75 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

IPA Stock Forecast (MarketRank)

Overall MarketRank

1.37 out of 5 stars

Medical Sector

1100th out of 1,417 stocks

Pharmaceutical Preparations Industry

545th out of 675 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
ImmunoPrecise Antibodies logo

About ImmunoPrecise Antibodies (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

IPA Stock News Headlines

ImmunoPrecise Antibodies (NASDAQ:IPA) Trading Up 9.9%
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$-5.62 million
Pretax Margin


Sales & Book Value

Annual Sales
$13.70 million
Book Value
$2.27 per share


Free Float
Market Cap
$102.75 million
Not Optionable

ImmunoPrecise Antibodies Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmunoPrecise Antibodies stock.
View analyst ratings for ImmunoPrecise Antibodies
or view top-rated stocks.

What is ImmunoPrecise Antibodies' stock price forecast for 2022?

1 analysts have issued 12-month price targets for ImmunoPrecise Antibodies' stock. Their IPA stock forecasts range from $12.00 to $12.00. On average, they expect ImmunoPrecise Antibodies' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 189.5% from the stock's current price.
View analysts' price targets for ImmunoPrecise Antibodies
or view top-rated stocks among Wall Street analysts.

How has ImmunoPrecise Antibodies' stock performed in 2022?

ImmunoPrecise Antibodies' stock was trading at $5.36 at the beginning of 2022. Since then, IPA stock has decreased by 22.7% and is now trading at $4.1450.
View the best growth stocks for 2022 here

Who are ImmunoPrecise Antibodies' key executives?

ImmunoPrecise Antibodies' management team includes the following people:
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Non-Independent Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Dr. Ilse Roodink, Chief Scientific Officer
  • Ms. Carla Dahl, VP of Marketing
  • Dr. Barry Neil Duplantis, VP of Client Relations

What is ImmunoPrecise Antibodies' stock symbol?

ImmunoPrecise Antibodies trades on the NASDAQ under the ticker symbol "IPA."

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (4.57%), Bank of Montreal Can (0.69%), Bank of America Corp DE (0.23%), JPMorgan Chase & Co. (0.10%), Dimensional Fund Advisors LP (0.06%) and Group One Trading L.P. (0.00%).

Which institutional investors are selling ImmunoPrecise Antibodies stock?

IPA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co..

Which institutional investors are buying ImmunoPrecise Antibodies stock?

IPA stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Bank of America Corp DE, Bank of Montreal Can, Dimensional Fund Advisors LP, and Group One Trading L.P..

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoPrecise Antibodies' stock price today?

One share of IPA stock can currently be purchased for approximately $4.15.

How much money does ImmunoPrecise Antibodies make?

ImmunoPrecise Antibodies (NASDAQ:IPA) has a market capitalization of $102.75 million and generates $13.70 million in revenue each year. The company earns $-5.62 million in net income (profit) each year or ($0.740010) on an earnings per share basis.

How many employees does ImmunoPrecise Antibodies have?

ImmunoPrecise Antibodies employs 73 workers across the globe.

How can I contact ImmunoPrecise Antibodies?

The official website for ImmunoPrecise Antibodies is www.immunoprecise.com. The company can be reached via phone at (250) 483-0308 or via email at [email protected].

This page (NASDAQ:IPA) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.